Siemens completed its acquisition of Diagnostic Products Corp. (DPC) in late July, marking a significant milestone for Siemens as it enters the in-vitro diagnostics (IVD) market. Together with DPC, Siemens Medical Solutions will become the first full service diagnostics company.
Founded in 1971, DPC is a global leader in immunodiagnostics, focusing on developing, manufacturing and distributing automated body fluid analyzers and tests, such as those related to cancer and cardiac disease, as well as hormone and allergy conditions.
This acquisition is just the first step for Siemens – on June 29, 2006, Siemens announced its intent to acquire Bayer Healthcare’s Diagnostics Division (subject to regulatory approvals).
According to Erich R. Reinhardt, president and CEO of Siemens Medical Solutions, the mergers will expand Siemens’ competencies in the innovative and fast-growing area of molecular medicine from in vivo molecular imaging, including, for example, PET imaging (positron emission tomography). Molecular medicine has the proven potential to enable healthcare professionals to identify risks for disease based on a patient’s genetics, and isolate the molecular makeup of an illness long before a patient ever experiences outward signs of disease.
Once the acquisition of Bayer Diagnostics is complete, Siemens will offer solutions in immunodiagnostics, genetic testing, near-patient testing, clinical chemistry, lab automation, hematology (blood cell diagnostics), and beyond. Siemens will bridge the gap between in-vivo and in-vitro diagnostics and offer a unique blend of expertise and technologies in diagnostic imaging, healthcare information technology (IT), molecular biology, and biochemistry to its customers, driving and leading the advancement of personalized healthcare.
For more information visit www.usa.siemens.com/medical-pressroom and www.dpcweb.com.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now